4//SEC Filing
Gaston-Dreyfus Remi 4
Accession 0001144204-18-019049
CIK 0001508381other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 6:53 PM ET
Size
14.9 KB
Accession
0001144204-18-019049
Insider Transaction Report
Form 4
Gaston-Dreyfus Remi
Director
Transactions
- Award
Warrant
2017-03-31+1,600,640→ 3,361,344 total(indirect: Warrants held through Lombard International Assurance SA)Exercise: $0.06From: 2018-03-31Exp: 2022-03-31→ Common Stock (1,600,640 underlying) - Conversion
Common Stock
2018-03-31$0.06/sh+63,197,149$3,949,822→ 75,463,389 total(indirect: Shares held through RGD Investissements) - Award
Warrant
2017-03-31+1,760,704→ 3,361,344 total(indirect: Warrants held through RGD Investissements)Exercise: $0.06From: 2018-03-31Exp: 2022-03-31→ Common Stock (1,760,704 underlying) - Conversion
Common Stock
2018-03-31$0.06/sh+12,266,240$766,640→ 75,463,389 total(indirect: Shares held through Lombard International Assurance SA) - Award
Warrant
2017-08-14+5,858,343→ 5,858,343 total(indirect: Warrants held through RGD Investissements)Exercise: $0.06From: 2018-03-31Exp: 2022-08-14→ Common Stock (5,858,343 underlying)
Footnotes (3)
- [F1]On March 31, 2018, an aggregate amount of $4,931,644 in convertible promissory notes converted in accordance with their terms into (i) 63,197,149 shares of the Issuer's common stock, and (ii) 15,740,728 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
- [F2]On March 31, 2018, an aggregate amount of $766,333 in convertible promissory notes converted in accordance with their terms into 12,266,240 shares of the Issuer's common stock.
- [F3]As of each of the transaction dates, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018.
Documents
Issuer
Bionik Laboratories Corp.
CIK 0001508381
Entity typeother
Related Parties
1- filerCIK 0001716639
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 6:53 PM ET
- Size
- 14.9 KB